Anti Lgi1 Antibody C5558416
Anti Lgi1 antibodies are linked to limbic encephalitis, causing seizures and memory problems. Treatment involves suppressing the immune response.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Sudden loss of consciousness
Seizures (often focal)
Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Facial twitching (facial myokymia)
(neurologic)Memory lapses and short‑term memory loss
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
First-line Immunotherapy
High-dose corticosteroid therapy is typically initiated as first-line treatment to suppress the autoimmune response targeting LGI1 receptors in the brain.
Additional treatment options
Plasma Exchange (PLEX)
Therapeutic plasma exchange removes pathogenic antibodies from circulation and may be used when rapid improvement is needed or as second-line therapy.
procedureAnti-seizure Medication
Antiseizure drugs are prescribed to manage faciobrachial dystonic seizures commonly associated with anti-LGI1 encephalitis.
medicationNeurorehabilitation
Comprehensive rehabilitation including physical and occupational therapy helps restore function and addresses residual motor and cognitive deficits.
physical_therapyRegular Neurological Monitoring
Scheduled follow-up with neurological examination, antibody titers, and imaging to assess treatment response and detect potential relapse.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti Lgi1 Antibody C5558416?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016.
van Sonderen A, Petit-Pedrol M, Dalmau J, Titulaer MJ. The value of LGI1 antibody testing in clinical practice. Neurology. 2022.
Irani SR, Gelfand JM, Al-Diwani A, Vincent A. Cell-surface CNS autoantibody disorders: a new frontier. Lancet Neurol. 2021.
Thompson J, Liguori G, Bien CG, et al. Long-term outcomes in patients with LGI1 antibody encephalitis. JAMA Neurol. 2023.
Medication Comparisons
Compare medications used to treat Anti Lgi1 Antibody C5558416. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy